Greater Cannabis Partners with Shaare Zedek Scientific on Innovative Neuropsychiatric Cannabinoid Therapy

Photo by Ousa Chea on Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Greater Cannabis Company, Inc. GCAN, a pioneer of cannabinoid pharmaceuticals and consumer products, has recently signed a licensing agreement with Shaare Zedek Scientific Ltd (SZS), the research and development subsidiary of Shaare Zedek Medical Center.

Greater Cannabis Company, Inc. is a Baltimore-based biopharmaceutical company specializing in developing and commercializing innovative cannabinoid therapeutics and consumer products. 

This latest partnership between Greater Cannabis and Shaare Zedek Scientific represents a critical step for ongoing clinical research of cannabinoid therapeutics in the field of pediatric neurology, as well as consumer product development. The agreement covers the license of SZS’s novel cannabinoid therapeutics geared toward the treatment of various neuropsychiatric disorders, including autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

Alongside the licensing agreement is a joint research and development agreement, with a focus on the clinical program headed by Dr. Adi Aran, Director of Pediatric Neurology at SZMC, board member of the Israeli Society for Pediatric Neurology and co-inventor of the novel cannabinoid therapy. 

Aran plays an instrumental role in worldwide cannabis research and pediatric neurology. He’s credited as the principal investigator of the first-ever double-blind, placebo-controlled cannabis study conducted on autistic children. Collaborating with Aran, Greater Cannabis Company will play a significant role in aiding the development of a novel therapy. 

Aran’s previous work assessed the safety, tolerability and efficacy of cannabidiol, CBD-based medical cannabis therapeutics for behavioral problems in children on the autism spectrum. 

The results of Aran’s study offers significant evidence that medical cannabis is an effective therapy for children with autism spectrum disorder (ASD). During trials, conditions in 80% of the children improved, and 62% of parents reported substantial improvements. About 50% of the children had better communication and 40% reported a decrease in anxiety. The same children had not shown advancements with conventional drug therapies. 

Aran and Greater Cannabis are now developing a novel combination therapy that is believed to be significantly more effective than the cannabis-only formulation that had been used in the study.

Aitan Zacharin, CEO of Greater Cannabis Company, stresses the significance of the collaboration. “We believe this newly identified therapeutic is going to open new pathways and opportunities across a range of indications within the pharmaceutical as well as the consumer health and wellness settings. We look forward to working together with Dr. Aran and his team to develop and deliver meaningful therapies, with a shared commitment of improving the lives of those suffering from neuropsychiatric disorders.”

Learn more about Greater Cannabis Company, its technology developments and investor relations here. 

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.